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Clusteringa b s t r a c t
The stress inducible heat shock protein 70 (Hsp70) is present speciﬁcally on the tumour cell surface
yet without a pro-tumour function revealed. We show here that cell surface localised Hsp70
(sHsp70) supports clathrin-independent endocytosis (CIE) in melanoma models. Remarkably, ability
of Hsp70 to cluster on lipid rafts in vitro correlated with larger nano-domain sizes of sHsp70 in high
sHsp70 expressing cell membranes. Interfering with Hsp70 oligomerisation impaired
sHsp70-mediated facilitation of endocytosis. Altogether our ﬁndings suggest that a sub-fraction of
sHsp70 co-localising with lipid rafts enhances CIE through oligomerisation and clustering.
Targeting or utilising this tumour speciﬁc mechanism may represent an additional beneﬁt for
anti-cancer therapy.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Members of the Hsp70 family assist in the folding of nascent or
misfolded proteins with an important role in cellular protein
homeostasis [1]. Frequently upregulated in tumour cells [2], indu-
cible Hsp70 (HSPA1A) exerts cytoprotective and anti-apoptotic
functions [3]. Unlike the constitutive homologue Hsc70, Hsp70 is
also known to be present at the extracellular leaﬂet of the plasma
membrane (surface Hsp70, sHsp70) of most tumour cells but not
that of the corresponding normal cells [4]. sHsp70 has been iden-
tiﬁed as a recognition feature for the immune system [5]. At the
same time, the concentration of sHsp70 has been shown to corre-
late with metastatic potential of B16 mouse melanoma cells [6]. As
surface localisation of Hsp70 is dependent on cholesterol content
of the membrane, sHsp70 is likely associated with ‘‘lipid rafts’’ [7].Given that Hsp70 is frequently upregulated in tumour cells,
where it is speciﬁcally present on the tumour cell surface, and that
derailed endocytosis is a feature of cancer [8], we hypothesized
that sHsp70 may have a general impact on the endocytic process.
We previously showed that overexpression of Hsp70 in B16 mouse
melanoma cells gave rise to the concentration of sHsp70 [9]. Here
we show for the ﬁrst time, using the B16 model and human A375
melanoma cells, that high levels of Hsp70 facilitate CIE even at
unstressed conditions. We further reveal that a sub-fraction of
sHsp70 localised in lipid rafts facilitates CIE through its oligomeri-
sation and clustering in the plasma membrane.
2. Materials and methods
Inducible cell lines of B16-F10 and A375 (ATCC, Manassas, VA,
USA) were generated by co-transfection of cells with pcDNA.6/TR
and with empty pcDNA.4/TO or pcDNA.4/TO-mHSP70 or
pcDNA.4/TO-mHsp70-E3. Stable clones were selected by media
containing Zeocin (Life Technologies) and Blasticidin (InvivoGen,
San Diego, CA, USA). B16-F10 cells were cultured in RPMI medium
(Life Technologies) supplemented with 10% FCS (Sigma-Aldrich, St.
Louis, MO, USA), 2 mM L-glutamine (Life Technologies), A375 cells
2748 B. Nimmervoll et al. / FEBS Letters 589 (2015) 2747–2753in DMEM/F12 (+L-glutamine) (Life Technologies) with 10% FCS (Life
Technologies). Hsp70 overexpression was induced by 2 lg/ml
doxycycline for 16 h, referred to as ‘‘Hsp70’’. Hsp70 expression
levels were tested by Western blotting and ﬂow cytometry.
Experiments with ﬂuorescent readout were performed in
OptiMEM supplemented with 1% FCS (Sigma).
To determine endocytic pathway activities, cells were incu-
bated for 5 min at 37 C with 7.5 lM FM4-64 (Sigma) or 1.5 lM
BODIPY-lactosylceramide (LacCer, Life Technologies) or 5 lg/ml
transferrin-AlexaFluor488 (Tf, Life Technologies). Following the
incubation, cells were washed twice in ice-cold medium. LacCer
was back-exchanged in 6  10 min washing steps with 5% defatted
BSA (Sigma) in ice-cold OptiMEM. Samples were analysed by ﬂow
cytometry (BD FACS Aria, Becton Dickinson, Franklin Lakes, NJ,
USA) with an excitation at 488 nm or 633 nm and detection at
530/30 nm or at 695/40 nm for Tf and LacCer or for FM4-64,
respectively. Debris and cells with damaged membranes were
gated by FSC vs. SSC plotting and propidium-iodide exclusion
(5 lg/ml, Sigma). The extracellular Tf signal was quenched by
0.1% trypan blue (Sigma).
For the identiﬁcation of sHsp70 endocytosis pathways, induced
cells were pre-incubated for 30 min with 10 lg/ml chlorpromazine
(Sigma) or 2 mM amantadine (Sigma) for inhibition of CDE or with
50 lg/ml nystatin (Millipore) or 1 mM methyl-b-cyclodextrin
(MbCD, Sigma) for inhibition of CIE. Then, Alexa488 labelled (Life
Technologies) cmHsp70.1 antibody (multimmune, München,
Germany) or appropriate isotype control (Sigma) was added
(1 lg/50 ll) at 37 C for 30 min for endocytosis. Cells were washed
in ice-cold medium and the intracellular ﬂuorescence was deter-
mined by ﬂow cytometry in the 530/30 nm channel. Live cell gat-
ing and quenching of extracellular signal were performed as
described above.
To inhibit endocytosis by sHsp70 immobilisation, 96-well
plates were coated with cmHsp70.1 or isotype control (2 mg/ml)
in a 0.05 M sodium carbonate buffer (pH 9.6), at 4 C overnight.
2 lm beads coated with goat anti-mouse IgG (chemicell, Berlin,
Germany) were loaded with cmHsp70.1 or isotype control
(2 lg/mg bead). 150 lg of beads were distributed per well and
incubated for 1 h at 37 C. To determine the endocytic activity, cells
were incubated in 100 ll of ice-cold medium containing 7.5 lM
FM4-64 (Sigma) for 5 min and endocytosis was initiated by releas-
ing the cold block at 37 C for another 5 min. Following extensive
washing, FM4-64 was excited at 500/9 nm and the ﬂuorescence
signal was measured at 730/20 nm in a plate reader (Tecan
Inﬁnite Pro, Tecan, Maennedorf, Switzerland). Cell-free wells
served as background control.
To study endocytosis in the presence of Hsp70 oligomerisation
inhibitors, cells plated onto 96-well plates were induced to overex-
press Hsp70 for 12 h. Next, cells were incubated with Hsp70 pep-
tide fragments generated as described in Aprile et al. [10] or with
BSA (10-1000 nM) at 37 C for 16 h. Then endocytosis of FM4-64
was measured as described above with the temperature block per-
formed at room temperature (20 C).
The Hsp70 surface distribution on cell surfaces was studied
under physiological conditions by simultaneous topography and
recognition imaging (TREC). TREC is based on atomic force micro-
scopy in combination with a recognition molecule on the tip of
the cantilever, which enables simultaneous sensing of topography
and recognition of proteins with nanometre accuracy. TREC was
performed on a commercially available AFM set-up, a PicoPlus
AFM 5500 (Agilent Technologies Inc., Chandler, AZ, USA) in mag-
netic AC (MAC) mode equipped with a PicoTREC box (Agilent
Technologies Inc., Chandler, AZ, USA). Here the magnetically coated
AFM tips (MACLevers, Type VII, Agilent Technologies Inc., AZ, USA)
were functionalized with an antibody directed against surface
Hsp70, isotype control, or the K4 peptide complementary for theE3 tag on transgenic Hsp70. See Supplementary material and
methods for full details.
For high-speed atomic force microscopy measurements 1 lg/ml
recombinant Hsp70 was incubated on a freshly cleaved mica sur-
face in PBS buffer for 5 min followed by several rinsing steps to
remove unattached molecules from the liquid cell. Supported lipid
bilayers in PBS buffer supplemented with 10 mM MgCl2 were pre-
pared from dioleoyl-phosphatidylcholine (PC)/octadecanoyl-sphin
gomyelin (SM)/cholesterol (65/25/10 molar ratio; Avanti Polar
Lipids Inc., Alabaster, AL, USA) vesicles as described in [11].
Values in the text and graphs are presented as mean ± S.D.
P-values are indicated in the graphs and were considered statisti-
cally signiﬁcant when <0.05.
For a complete list of materials and methods used in this study
please refer to the Supplementary information.
3. Results and discussion
TodeterminewhetherHsp70 expression levels generally have an
impact on the endocytic activity in unstressed cells, we used stably
transfected tetracycline-inducible systems for Hsp70 overexpres-
sion in mouse B16 and human A375 melanoma cells (Hsp70) [9].
Cells stably transfected with empty vector served as control (ctrl).
Wemeasured the activity of endocytic pathways through theuptake
of the established ﬂuorescent tracers FM4-64 for general endocytic
activity, transferrin-AlexaFluor488 (Tf) for clathrin-dependent
endocytosis (CDE) and BODIPY-lactosylceramide (LacCer) for
clathrin-independent endocytosis (CIE) [12]. Upon Hsp70 overex-
pression in B16 and A375 cells, uptake of LacCer was signiﬁcantly
increased, while Tf uptake was slightly reduced (Fig. 1A). The latter
observation was somewhat surprising, as previous reports on hepa-
toblastoma cells showed enhanced CDE, yet upon heat shock or
pharmacological Hsp70 induction [13]. In fact, at stress conditions
Hsp70 has been proposed to be able to substitute for Hsc70 in cla-
thrin coat disassembly during CDE. In this current study, endocyto-
sis has been measured at unstressed conditions, and a slight
decrease in CDE may be attributed to excess of sHsp70 competing
with Tf as a substrate of CDE. This explanation is supported by the
fact that a large fraction of sHsp70 (60%) is endocytosed via CDE
(Fig. 1B). Importantly, B16 cells with low basal level of Hsp70 dis-
played a considerable increase (+30.0%) in their general endocytosis
levels, attributable to an increase in CIE. A smaller difference mea-
sured for A375 cells with high basal level of Hsp70 pointed to a sat-
urating effect of overexpression (Fig. 1C). Given the higher response
upon Hsp70 overexpression, B16 cells and the robust marker
FM4-64 were used in further experiments.
As an attempt to speciﬁcally interfere with Hsp70-mediated
endocytosis, we applied a speciﬁc antibody (cmHsp70.1) recognis-
ing the substrate-binding subdomain (SBSD) of sHsp70.
Apparently, this treatment had no effect on endocytosis (Fig. 1D),
indicating that substrate binding of Hsp70 may not be necessary
for Hsp70-mediated endocytosis. Since the Hsp70-antibody adduct
retains mobility of sHsp70 [9], we next targeted sHsp70 by
anti-Hsp70 antibody (cmHsp70.1) immobilised on bead and well
surfaces (see drawing in Fig. 1E). Importantly, this approach was
speciﬁc to sHsp70 and revealed a sizeable facilitation of endocytosis
by sHsp70 inHsp70overexpressing cells (44.5%and18.3% inhibition
with antibody-coated bead + well and bead surfaces, respectively).
It is noted that no signiﬁcant inhibition of endocytosis was detected
for control, low Hsp70 expressing cells (data not shown). As soluble
anti-Hsp70 antibody did not have any effect on FM4-64 uptake of
Hsp70 overexpressing cells (Fig. 1D), we conclude that limiting
Hsp70 mobility itself, and no other eventually allosteric effects
induced by the antibody, reduced endocytic activity.
The ﬁnding that mobility of sHsp70 was required for its effect
on endocytosis indicated that stimulation of endocytosis required
Fig. 1. Cell surface localised Hsp70 facilitates clathrin-independent endocytosis. (A) Activity of endocytosis pathways at different levels of intracellular Hsp70. Uptake of the
ﬂuorescent, pathway speciﬁc endocytosis tracers FM4-64 for total endocytosis, Alexa488-conjugated transferrin (Tf) for clathrin-dependent endocytosis and Bodipy-FL
labelled lactosylceramide (LacCer) for clathrin-independent endocytosis was examined by ﬂow cytometry in Hsp70 overexpressing mouse B16-F10 (B16) and human A375
melanoma cell lines (two-sided t-test, P-values indicated in the graph; n = 9–12; N = 3). (B) Endocytosis pathways utilised by Hsp70 in B16 cells. Endocytic pathways were
speciﬁcally blocked with the clathrin-dependent endocytosis (CDE) inhibitors chlorpromazine (CPZ) and amantadine or with the clathrin-independent (CIE) endocytosis
inhibitors methyl-b-cyclodextrin (MbCD) and nystatin. Endocytosis of Hsp70 was followed with Alexa488-conjugated cmHsp70.1 antibody and determined by ﬂow
cytometry. Indicated signiﬁcance levels refer to the respective untreated condition. Hsp70 overexpression did not affect sHsp70 uptake routes (P = 0.829). (General linear
model and subsequent Tukey’s test; n = 8-15; N = 2–3). (C) Western blot analysis of Hsp70 expression levels in control (ctrl) and Hsp70 overexpressing cells. (D) FM4-64
uptake determined by ﬂow cytometry in Hsp70 overexpressing B16 cells treated with anti-Hsp70 antibody (cmHsp70.1) or isotype control (one-way ANOVA; n = 11-12;
N = 3). (E) FM4-64 uptake in Hsp70 overexpressing cells in the presence of anti-Hsp70 antibody coated beads and well surfaces immobilising sHsp70 was followed on a plate
reader (one-sided t-test; n = 9–14; N = 3).
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Fig. 2. Hsp70 accumulates in enlarged clusters in Hsp70 overexpressing B16 cell membranes. (A)–(C) Nano-organisation of Hsp70 on the cell surface. Control (ctrl), Hsp70
and Hsp70 conjugated to an E3 tag overexpressing cells were ﬁxed and imaged by atomic force microscopy dynamic recognition imaging (TREC). Hsp70 was recognised by
cmHsp70.1 antibody or E3-complement peptide K4 linked to the cantilever, respectively (red areas). The topography is displayed in grey, the scale bar is 200 nm. (D) Relative
Hsp70 cluster size distribution based on Hsp70 recognition images (one-way ANOVA and subsequent Tukey’s test; n = 3–4; N = 3).
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tion with other proteins. As clustering has been shown to facilitate
endocytosis of diverse proteins such as LDL-receptors, amyloid
precursor protein or b1 integrin in both clathrin-dependent and
-independent pathways [14–16], we hypothesized a similar mech-
anism for sHsp70-mediated endocytosis. To understand whetherFig. 3. Hsp70 oligomerises on amica support and clusters on lipidmembrane domains in v
Movie E1). Average height of Hsp70 over support was 3.2 ± 0.4 nm (n = 112). Scale bar, 2
bacterial homologue DnaK (PDB 2KHO) identiﬁes the visualised structure as the N-termi
domain linker (linker) and substrate-binding domain (SBD). SBD consists of the substrate
Schematic representation of the primary structure of human Hsp70. Residues removed in
mica (see Movie E2) reveals a dynamic nature of Hsp70 dimers as NBD1 moves around N
distances of the centre of mass (COM) of NBD1 and NBD2 derived fromMovie E2. (F) High-
SM/cholesterol (see Movie E3). Average height of Hsp70 over themembrane support was 2
membrane topography images (n = 8) taken from the movie. Scale bar, 100 nm. (G) Ana
(47.4 ± 0.4% of Hsp70 particles, upper panel) and amobile fraction (lower panel). D is diffu
Hsp70 on a PC/SM/cholesterol model membrane identifying the NBD as membrane anchoHsp70 clusters exist on the cell surface and whether their size cor-
relates with the effects of Hsp70 overexpression on endocytosis,
we studied the nano-organisation of sHsp70 on ctrl, Hsp70 and
E3 tagged Hsp70 overexpressing cells [17]. Using an atomic force
microscopy cantilever conjugated to anti-Hsp70 antibody or to
an E3 interacting K4 peptide, both topography and sHsp70 speciﬁcitro. (A) Hsp70 onmica surface visualised by high-speed atomic forcemicroscopy (see
00 nm. (B) Superimposition of mica-bound Hsp70 with the crystal structure of the
nal nucleotide binding domain (NBD). Other structural domains are shown as inter-
-binding subdomain (SBSD) and the helical lid subdomain (HLS). Scale bar, 4 nm. (C)
the truncation mutants (Fig. 4) are shaded. (D) High resolution imaging of Hsp70 on
BD2. At 31090.5 ms trimerisation was observed. Scale bar, 5 nm. (E) Trajectories and
speed atomic force microscopy imaging of Hsp70 on amodel membranemade of PC/
.1 ± 0.7 nm (n = 20). Individual trajectories of Hsp70s are displayed on the average of
lysis of Hsp70 trajectories recorded on the model membrane yielded an immobile
sion coefﬁcient, PA is positional accuracy. (H) High-speed atomic force microscopy of
ring domain (compare to Fig. 3B). Scale bar, 10 nm.
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[18]. The Hsp70-E3/K4 system served as a control for the
Hsp70/antibody system. As shown in Fig. 2, recognition maps (dis-
played in red) revealed that sHsp70 tended to accumulate in
nano-domains (or clusters). In agreement with our hypothesis, a
remarkable increase in cluster size from small (6300 nm2, equiva-
lent circular ø 20 nm) and medium (>300 nm2, <4000 nm2) to
large clusters (P4000 nm2, equivalent circular ø 70 nm) was
observed as a result of Hsp70 overexpression. The larger cluster
sizes of sHsp70 were also paralleled with a twofold increase in
the surface density of Hsp70 on Hsp70 overexpressing cells com-
pared to control (see Table E1), matching our previous data
acquired by ﬂow cytometry [9].
A possible factor that may facilitate clustering of sHsp70 is
oligomerisation. In line with previous data obtained with biochem-
ical measurements [10], dimers and higher order oligomers of
recombinant human Hsp70 could be visualised by high resolution,
high-speed atomic force microscopy at a liquid-solid interface [19].
Remarkably, Hsp70 monomers, dimers and higher oligomers all
had a regular height of 3.2 ± 0.4 nm indicating a uniform orienta-
tion on the support (Fig. 3A; Movie E1). Analysing the recombinant
protein sample at higher resolution, the nucleotide-binding
domains (NBDs) of dimers and trimers could be clearly identiﬁed.
The substrate-binding domains (SBDs) were poorly resolved likely
due to their lack of association to the surface and their ﬂexible con-
nection to the NBD via the linker domain (Fig. 3B–D). Analysis of
trajectories of NBDs of the same molecule revealed a fairly stable,
yet ﬂexible and dynamic dimer structure with an average distance
of 9.7 ± 0.9 nm between the NBDs (Fig. 3D and E; see Movie E2). A
dynamic formation of trimers was also evident (Fig. 3D).Fig. 4. De-oligomerising fragments of recombinant Hsp70 impair endocytosis in B16 cells
(B) FM4-64 uptake in Hsp70 overexpressing cells treated with fragments SBD641, DLSBD
reader (one-way ANOVA and subsequent Tukey’s test; 10 nm n = 17–12, N = 5; 100 nmThe partial uptake of sHsp70 via the cholesterol-dependent CIE
(Fig. 1B) and the afﬁnity of Hsp70 to speciﬁc lipids such as choles-
terol [7,20], may further support accumulation and clustering of
sHsp70 in cholesterol-enriched lipid rafts. To test this idea, interac-
tion of recombinant Hsp70 with a supported bilayer was moni-
tored by high-speed atomic force microscopy. A segregated lipid
layer of PC/SM/cholesterol was used as an artiﬁcial model, where
lower non-raft and higher raft-like lipid domain areas were appar-
ent [21]. Hsp70 added to the lipid layer essentially localised and
clustered on the elevated, raft like domains (Fig. 3F). With nearly
equal probability, a practically immobile and a mobile fraction of
Hsp70 could be detected in all lipid domains analysed (Fig. 3G,
see Movie E3). Notably, the reduced average height of Hsp70 on
the lipid bilayer (2.1 ± 0.7 nm), as compared to impenetrable mica
(3.2 ± 0.4 nm), indicated a partial insertion of Hsp70 into the lipid
layer (Fig. 3A and F; P < 0.001). Furthermore, time-resolved
high-resolution images revealed the NBD as the lipid interaction
site (Fig. 3H). This ﬁnding was in good agreement with previous
reports on a single amino acid mutation in the NBD that impaired
Hsp70 membrane interaction [22,23]. Taken together, these data
showed that Hsp70 was able to interact with artiﬁcial lipid mem-
branes via its NBD domain and accumulated in raft-like lipid
domains, where it oligomerised and formed clusters.
Finally, to test if Hsp70 self-organisation stimulates endocytosis,
we used fragments of the recombinant human Hsp70 with
impaired oligomerisation properties, hence capable of interfering
with the oligomerisation of wt full length Hsp70. It has been
recently proposed that Hsp70 oligomerisation is mediated by the
inter-domain linker (linker), connecting the NBD and the SBD,
and the C-terminal part of the helical lid subdomain (HLS) of the. (A) Schematic drawing of Hsp70 fragments interacting with the full length protein.
641, SBD556 or BSA at the given concentrations overnight was followed on a plate
n = 8–9, N = 2; 1000 nm n = 17–23, N = 5).
Fig. 5. Schematic model for surface localised Hsp70-mediated facilitation of endocytosis in cancer cells. In control cells with low level of Hsp70, tumour cell surface localised
Hsp70 (sHsp70) is localised in smaller size clusters on the plasma membrane. Upregulating intracellular Hsp70 expression, as in various forms of cancer [2], is accompanied
with an elevated sHsp70 concentration [9]. sHsp70 at higher concentration forms larger clusters on the plasma membrane, which enables facilitation of CIE. Immobilisation
or de-oligomerisation of sHsp70 interfere with sHsp70-mediated facilitation of endocytosis, indicating that dynamics of sHsp70 as well as its ability to oligomerise are
important to exert an effect on endocytosis.
2752 B. Nimmervoll et al. / FEBS Letters 589 (2015) 2747–2753SBD [10]. By adding SBD fragments of recombinant human Hsp70
lacking either of the two oligomerisation interfaces (DLSBD641
variant without the linker and SBD556 variant without the
C-terminal part of the HLS; see Figs. 3C and 4A) to Hsp70 overex-
pressing cells, we expected to reduce sHsp70 oligomerisation,
hence endocytosis. As these fragments lacked the NBD domain,
we thereby eliminated potential binding of the fragments to the cell
membrane (Fig. 3H). Indeed, interfering with oligomerisation of
sHsp70 by the SBD556 and DLSBD641 fragments signiﬁcantly
reduced the FM4-64 uptake in a concentration dependent manner
(Fig. 4B, up to 27.7% inhibition). In contrast, neither inert BSA nor
a control fragment with the two fully functional oligomerising
interfaces, did affect endocytosis at any concentration tested. It
should be noted that administeringwithwt full length recombinant
Hsp70 slightly increased FM4-64 uptake (data not shown). It is also
noteworthy that extent of the observed inhibition was comparable
to the stimulation of endocytosis byHsp70 overexpression (Fig. 1A),
supporting the idea of an oligomerisation dependent mechanism.
In conclusion, we propose a novel function of the cell surface
localised Hsp70 as a stimulator of CIE. Accumulation of overex-
pressed Hsp70 in large size nano-domains on the cell surface, par-
alleled with a reversible increase in endocytosis driven by sHsp70
oligomerisation, strongly suggest a clustering dependent mecha-
nism for sHsp70-mediated increase in endocytosis (Fig. 5).
Interestingly, oligomerisation was previously described as a
requirement for raft-association and transcytosis of GPI-GFP
[24,25] as well as for the recognition and internalisation of toxic
amylin [26]. Here we ﬁrst describe sHsp70 as a potential regulator
of such oligomerisation and clustering dependent endocytic
events. Preferential interaction of Hsp70 with speciﬁc lipids, its
ability to cluster on cell membranes and its chaperone function
support a signiﬁcant role for sHsp70 in endocytosis. In line with
this argument, clustering and interaction of speciﬁc surface mole-
cules with lipid rafts are thought to enable formation of membrane
curvature and invagination, hence initiating endocytosis even
without adaptor proteins at the cytosolic side [27,28]. We suggest
that sHsp70, when present in cancer cell membranes, may facili-
tate the raft associated CIE in an analogous manner. Revealing
additional components of the CIE machinery and further under-
standing of the mechanism of action of known regulators, such
as glycosphingolipids, Galectin-3 or sHsp70 will be fostering this
emerging ﬁeld [27].
Altered endocytosis is a typical feature of cancer, where
dynamic remodelling and recycling routes at the plasma mem-
brane support tumour cell survival and progression [8]. As Hsp70is frequently upregulated in tumours, the resulting increased
sHsp70 levels [4,9] could stimulate endocytosis for the beneﬁt of
the tumour [29,30]. Inhibition of the sHsp70-mediated stimulation
of endocytosis, as shown in this study, may therefore represent an
adjuvant therapeutic strategy against cancer. At the same time,
tumour speciﬁc surface localisation of Hsp70 allows speciﬁc drug
targeting of cancer cells [31,32], where sHsp70-mediated increase
in endocytosis would enhance the efﬁciency of drug treatment.
sHsp70-mediated stimulation of endocytosis, reported in this
paper, represents a novel cancer speciﬁc mechanism and further
validates the tumour marker sHsp70 for efﬁcient anti-cancer drug
delivery. In future, we aim to follow our current working hypothe-
sis in order to characterise the mechanism of regulation of endocy-
tosis by sHsp70.Competing interest
The authors declare no competing interests.
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